Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 8/20 | 0.55 |
| ▸ | PPARD | Q03181 | 6/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6483699 | 0.91 | FFAR1 (0.57) | FFAR1PPARDFFAR4 | |
| SCHEMBL6474071 | 0.89 | FFAR1 (0.55) | FFAR1PPARDFFAR4TP53MDM2 | |
| SCHEMBL6474624 | 0.88 | PPARD (0.65) | FFAR1PPARDFFAR4MRGPRX4 | |
| SCHEMBL6482973 | 0.88 | PPARD (0.65) | FFAR1PPARDMRGPRX4 | |
| SCHEMBL6529335 | 0.88 | FFAR1 (0.60) | FFAR1PPARDFFAR4TP53MDM2 | |
| SCHEMBL6480732 | 0.86 | PPARD (0.58) | FFAR1PPARDFFAR4 | |
| SCHEMBL6482698 | 0.86 | FFAR1 (0.52) | FFAR1PPARDFFAR4 | |
| SCHEMBL6480222 | 0.84 | PPARD (0.62) | FFAR1PPARDFFAR4MRGPRX4 | |
| SCHEMBL6480739 | 0.82 | FFAR1 (0.48) | FFAR1PPARDFFAR4 | |
| SCHEMBL6483729 | 0.82 | FFAR1 (0.48) | FFAR1PPARDFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869967-B2 | Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | claimed |
| EP-1414778-A1 | NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC. | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | EP | claimed |
| US-20030139473-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-07-24 | — | — | US | claimed |
| WO-2003011807-A1 | NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC. | NOVO NORDISK A/S (DK) | 2003-02-13 | — | — | WO | claimed |
| US-6869967-B2 | Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | disclosed |
| US-20030139473-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139473-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | FFAR1 22/4885PPARD 2/4885FFAR4 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.